Karen E. Knudsen, PhD, discusses the greater significance of the INTerpath-001 results of intismeran autogene in resectable ...

The FDA granted RMAT and fast track designations to prizloncabtagene autoleucel , a CD20/CD19 bispecific CAR T-cell therapy, for relapsed/refractory large B-cell lymphoma.

During a live event, Rushang Patel, MD, PhD, and participants discussed referral timing, bridging, and payer barriers that ...

The FDA has approved the PCR-based OncoMate MSI Dx Analysis System as a companion diagnostic to identify MSI-H solid tumors ...

Benjamin Garmezy, MD, discusses how JNJ-6143 uses a novel RIPTAC mechanism to target AR and BRD4, potentially addressing resistance-associated genomic alterations in advanced prostate cancer.

Jacob Sands, MD, of Dana-Farber Cancer Institute, discusses survival gains, durability, and safety of tarlatamab plus durvalumab in the phase 3 DeLLphi-305 trial.

Kohei Shitara, MD, discusses HERIZON-GEA-01 findings and how to individualize first-line treatment for HER2-positive advanced ...

Arvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.

Arvind N. Dasari, MD, MS, reviews a year in neuroendocrine tumors marked by expanding radioligand options, improved ...

Among patients surveyed, 92% preferred home-based treatment, while nationwide modeling projected substantial savings in ...